Rybelsus vs. Farxiga

Rybelsus (semaglutide) and Farxiga (dapagliflozin) are used as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Rybelsus and Farxiga belong to different drug classes. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist and Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Side effects of Rybelsus and Farxiga that are similar include nausea and constipation.

Side effects of Rybelsus that are different from Farxiga include abdominal pain, diarrhea, decreased appetite, and vomiting.

Side effects of Farxiga that are different from Rybelsus include yeast infections of the vagina or penis, urinary tract infections, changes in urination (including urgent need to urinate more often, discomfort when urinating, urinating in larger amounts, or at night), sore throat, runny or stuffy nose, back pain, influenza, elevated cholesterol or fat in the blood, and pain in the extremities.

Rybelsus may interact with insulin secretagogues or insulin, and other oral medications taken at the same time.

Farxiga may interact with other drugs.

Common side effects of Rybelsus include:

• nausea,
• abdominal pain,
• diarrhea,
• decreased appetite,
• vomiting, and
• constipation

Common side effects of Farxiga include:

• yeast infections of the vagina or penis,
• urinary tract infections,
• changes in urination (including urgent need to urinate more often, discomfort when urinating, urinating in larger amounts, or at night),
• sore throat,
• runny or stuffy nose,
• back pain,
• nausea,
• influenza,
• constipation,
• elevated cholesterol or fat in the blood, or
• pain in the extremities.

Rybelsus (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Farxiga (dapagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Farxiga may interact with other drugs. Tell your doctor all medications and supplements you use.

Farxiga may interact with monoamine oxidase inhibitors (MAOIs), opioid-containing medicines (such as cough and cold remedies, antidiarrheal drugs, and opioid analgesics), antidepressants, antipsychotics, beta-blockers, antiarrhythmics, ticlopidine, clopidogrel, ritonavir, lopinavir, efavirenz, theophylline, corticosteroids, levodopa, amantadine, and alcohol. Tell your doctor all medications and supplements you use. Farxiga is not recommended for use during pregnancy.

The initial dose of Rybelsus is 3 mg once daily for 30 days. After 30 days on the 3 mg dose, increase the dose of Rybelsus to 7 mg once daily.

The recommended starting dose of Farxiga is 5 mg once daily, taken in the morning, with or without food.